Valuation : Coya Therapeutics, Inc.

Market Cap 107M 91.84M 86.41M 78.94M 148M 10.08B 148M 1.02B 396M 5.17B 401M 392M 16.66B P/E 2026 *
-3.59x
P/E 2027 * -3.33x
Enterprise Value 107M 91.84M 86.41M 78.94M 148M 10.08B 148M 1.02B 396M 5.17B 401M 392M 16.66B EV / Sales 2026 *
105x
EV / Sales 2027 * 21.5x
Free-Float
83.27%
Yield 2026 *
-
Yield 2027 * -
1 day+4.62%
1 week+3.70%
Current month+4.39%
1 month+4.16%
3 months-2.26%
6 months-3.45%
Current year-17.93%
1 week 4.36
Extreme 4.36
4.77
1 month 4.36
Extreme 4.36
5.26
Current year 3.71
Extreme 3.7101
6.21
1 year 3.71
Extreme 3.7101
7.75
3 years 3.21
Extreme 3.21
10.69
5 years 3.21
Extreme 3.21
10.69
10 years 3.21
Extreme 3.21
10.69
Manager TitleAgeSince
Chief Executive Officer 57 2024-10-31
President 67 2023-07-16
Director of Finance/CFO 65 2022-03-29
Director TitleAgeSince
Director/Board Member 58 2021-02-28
Director/Board Member 67 2021-05-24
Director/Board Member 64 2021-05-31
Date Insider Type Main position Quantity % Market Cap. Importance
4/9/26 Free

Director

10,000 0.0426%
1/22/26 Free

Chief Financial Officer

140,041 0.6693%
1/22/26 Free

Chief Executive Officer

15,257 0.0729%
Change 5-day change 1-year change 3-year change Capi.($)
+4.62%+3.70%-25.39%+15.82% 107M
-2.54%-3.60%-0.60%+15.17% 50.35B
-0.40%+1.03%+439.20%+523.39% 45.2B
-1.42%+2.05%+45.04%+19.36% 44.71B
-1.22%-2.31%+12.40%+74.90% 41.24B
+0.53%-1.67%+15.16%+49.88% 33.08B
-0.21%+9.14% - - 17.81B
-0.35%-1.56%+22.59%+123.04% 16.56B
-1.01%-0.38%+15.69%+28.39% 14.82B
-1.65%-2.67%+77.72%+37.63% 14B
Average -0.57%-0.63%+66.87%+98.62% 27.79B
Weighted average by Cap. -1.38%-0.47%+94.36%+126.94%

Financials

2026 *2027 *
Net sales 1.02M 876K 825K 753K 1.41M 96.17M 1.41M 9.74M 3.78M 49.34M 3.82M 3.74M 159M 4.96M 4.27M 4.02M 3.67M 6.86M 468M 6.88M 47.47M 18.42M 240M 18.63M 18.23M 774M
Net income -30.48M -26.23M -24.67M -22.54M -42.17M -2.88B -42.28M -292M -113M -1.48B -114M -112M -4.76B -33.18M -28.55M -26.86M -24.54M -45.91M -3.13B -46.03M -317M -123M -1.61B -125M -122M -5.18B
Net Debt - -
Logo Coya Therapeutics, Inc.
Coya Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in developing treatments focused on the biology and potential therapeutic advantages of regulatory T cells (Tregs) to target systemic inflammation and neuroinflammation. Its initial developmental programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases of high unmet medical need. Its diversified candidate pipeline includes both ex vivo and in vivo approaches. Its product candidate pipeline is based on its three therapeutic modalities. The product candidates utilizing its Treg-enhancing biologics are collectively referred to as the 300 Series. The product candidates utilizing its Treg-derived exosomes are collectively referred to as the 200 Series. The product candidates utilizing its autologous Treg cell therapy are collectively referred to as the 100 Series. The Company's 300 Series product candidates include COYA 301 and COYA 302.
Employees
8
Date Price Change Volume
26-09-04 US$4.760 +4.62% 75,638
26-09-03 US$4.550 +2.94% 100,315
26-09-02 US$4.420 -2.00% 61,902
26-09-01 US$4.510 -1.10% 101,246
26-08-31 US$4.560 -0.65% 47,432
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.550USD
Average target price
15.21USD
Spread / Average Target
+234.38%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. COYA Stock